A Poorly Differentiated Malignant Neoplasm Lacking Lung Markers Harbors an EML4-ALK Rearrangement and Responds to Crizotinib
Suspected metastatic site lesions that are poorly differentiated present a diagnostic challenge when morphologic and immunohistochemical profiling cannot establish the primary tumor site. Here we present a patient diagnosed with both a malignant neoplasm in the lung and a right upper extremity (RUE)...
Main Authors: | Jon H. Chung, Siraj M. Ali, Jenni Davis, Karl Robstad, Richard McNally, Laurie M. Gay, Rachel L. Erlich, Norma A. Palma, Phil J. Stephens, Vincent A. Miller, Alfonso Cutugno, Jeffrey S. Ross |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2014-09-01
|
Series: | Case Reports in Oncology |
Subjects: | |
Online Access: | http://www.karger.com/Article/FullText/367780 |
Similar Items
-
The Impact of Clinical Factors, ALK Fusion Variants, and BIM Polymorphism on Crizotinib-Treated Advanced EML4–ALK Rearranged Non-small Cell Lung Cancer
by: Yen-Ting Lin, et al.
Published: (2019-09-01) -
lincROR influences the stemness and crizotinib resistance in EML–ALK+ non-small-cell lung cancer cells
by: Yang Y, et al.
Published: (2018-06-01) -
NCOA1–ALK: a novel ALK rearrangement in one lung adenocarcinoma patient responding to crizotinib treatment
by: Cao Q, et al.
Published: (2019-02-01) -
Patients harboring ALK rearrangement adenocarcinoma after acquired resistance to crizotinib and transformation to small-cell lung cancer: a case report
by: Zhu Y, et al.
Published: (2017-06-01) -
Response to crizotinib in a non-small-cell lung cancer patient harboring an EML4-ALK fusion with an atypical LTBP1 insertion
by: Aguado C, et al.
Published: (2018-03-01)